NEWS

New Drug QZYTIRTM for Acute Urticaria Has Submitted NDA to FDA

Release time:

2018-12-28 17:10

Due to the change of climate and environment, a variety of harmful gases, dust and other pollution sources have emerged in large numbers, making it a allergen that causes people to have a variety of allergic reactions. Cetirizine has no effect on mast cells in the allergen immunity test, but inhibits the response of neutrophils and platelets. Cetirizine oral tablets have been used since 1995 to treat seasonal allergic rhinitis (allergic rhinitis, hay fever), dermatitis, conjunctivitis, asthma, chronic urticaria, etc.

JDP Therapeutics Inc.is a pharmaceutical company focused on the development of small molecule therapeutics, and its main drug candidate QZYTIRTM is now in 2018.The key phase 3 clinical trial for acute urticaria was successfully completed in June, and NDA was submitted to FDA in early December 2018. If approved by the US Food and Drug Administration (FDA), QZYTIRTM may become the only product suitable for acute urticaria.

 

What is acute urticaria?

In recent years, the frequency of acute allergic reactions has increased year by year, which may be due to the increase in the number of potential allergens to which people are exposed, such as the increasing variety of foods and medicines. Recent reviews have found that the prevalence of acute anaphylaxis, including anaphylaxis, is about 5% of the total population, with higher prevalence in developed countries than in developing countries, and acute anaphylaxis occurs in all age groups.

Acute urticaria, the most common symptom of acute allergic reactions, is a serious and potentially life-threatening disease for which treatment options are very limited, QZYTIRTM (cetirizine IV) will provide better quality treatment for the treatment methods that have been used for the past 65 years.

About QZYTIRTM

QZYTIRTMIt is a patented injectable product of cetirizine (cetirizine IV), an extremely effective antihistamine drug used to treat acute urticaria; due to the acute nature of the disease, there is a need for an injectable and immediate product.

A third-party authoritative market survey of 110 doctors showed that 86 of them% of doctors expressed their willingness to use QZYTIRTM instead of the current diphenhydramine injection therapy. At the same time, doctors believe that QZYTIRTM does not have the related side effects of diphenhydramine, which is the most convincing reason to support QZYTIRTM treatment; two other independent Market research and in-depth clinician interviews also confirmed that QZYTIRTM will be able to meet the current treatment needs.

Related Patent Information

JDP Therapeutics Inc.

ØBeijing Koxin Bicheng Pharmaceutical Technology

 

JDP Therapeutics Inc.Since June 2016In January, it received round A financing from Beijing Kexin Bicheng Pharmaceutical Technology Development Co., Ltd. for key Phase 3 clinical trials of its main drug candidates, submission of NDA and listing approval.

*Cetirizine is the precursor of levocetirizine. After cetirizine enters the body, it is converted into levocetirizine under the action of liver enzymes to play an anti-allergic effect; after levocetirizine enters the body, it does not need to go through the transformation of the liver and can directly play an anti-allergic effect.

Presentation, Acute, qzytirtm, Treatment, Allergic reactions, Urticaria, Doctors, Medicines, Products, therapeutics